Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3847700

C[n+]1ccn(CC(=O)c2ccc(Cl)cc2Cl)c1.[Cl-]

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 2/20 0.52
ALDH1A1 P00352 2/20 0.50
MAPK1 P28482 1/20 0.50
HIF1A Q16665 1/20 0.50
POLB P06746 3/20 0.49
ERCC5 P28715 1/20 0.46
FEN1 P39748 1/20 0.46
TSHR P16473 1/20 0.42
CASP1 P29466 1/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
P2RX7 Q99572 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
PAX8 Q06710 1/20 0.41
KLF5 Q13887 1/20 0.41
CA9 Q16790 1/20 0.41
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20527637 0.81 LMNA (0.72) SMN1; SMN2LMNAALDH1A1MAPTKDM4E
Hydrochloric Acid SCHEMBL3848623 0.78 POLB (0.53) SMN1; SMN2LMNAALDH1A1MAPK1HIF1A
SCHEMBL20527454 0.78 LMNA (0.63) SMN1; SMN2LMNAALDH1A1CA12CA1
SCHEMBL20527661 0.78 LMNA (0.59) SMN1; SMN2LMNAALDH1A1ERCC5FEN1
SCHEMBL20363960 0.77 ALDH1A1 (0.54) SMN1; SMN2LMNAALDH1A1MAPK1HIF1A
Hydrochloric Acid SCHEMBL6944291 0.76 POLB (0.55) SMN1; SMN2LMNAALDH1A1MAPK1POLB
SCHEMBL6941358 0.75 POLB (0.56) SMN1; SMN2LMNAALDH1A1MAPK1POLB
SCHEMBL20527659 0.74 LMNA (0.55) SMN1; SMN2LMNAMAPK1ERCC5FEN1
Hydrochloric Acid SCHEMBL29873211 0.73 LMNA (0.64) SMN1; SMN2LMNATDP1L3MBTL1
SCHEMBL20527617 0.73 LMNA (0.53) SMN1; SMN2LMNAALDH1A1ERCC5FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2085086-A2 Method for treating congestive heart failure or diabetic nephropathy Synvista Therapeutics, Inc. (US) 2009-08-05 EP disclosed
US-20090124674-A1 Method for treating congestive heart failure SYNVISTA THERAPEUTICS, INC. (US) 2009-05-14 US disclosed
US-20090124673-A1 Method for treating diabetic nephropathy SYNVISTA THERAPEUTICS , INC. (US) 2009-05-14 US disclosed
US-7432254-B2 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. (US) 2008-10-07 US disclosed
US-20070043016-A1 Method of treating fibrotic diseases or other indications with imidazolium agents SYNVISTA THERAPEUTICS, INC. 2007-02-22 US disclosed
US-7166625-B2 Method for treating fibrotic diseases and other indications ALTEON, INC. (US) 2007-01-23 US disclosed
EP-1305024-A4 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON INC (US) 2006-03-22 EP disclosed
EP-1353669-A4 METHOD FOR TREATING GLAUCOMA IB ALTEON INC (US) 2005-10-19 EP disclosed
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE SYNVISTA THERAPEUTICS, INC. 2004-11-25 US disclosed
EP-1353669-A1 METHOD FOR TREATING GLAUCOMA IB Alteon, Inc. (US) 2003-10-22 EP disclosed
US-20030176426-A1 Method for treating fibrotic diseases or other indications with imidazolium agents ALTEON, INC. 2003-09-18 US disclosed
EP-1305024-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC Alteon, Inc. (US) 2003-05-02 EP disclosed
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID SYNVISTA THERAPEUTICS, INC. 2002-11-28 US disclosed
US-20020160993-A1 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. 2002-10-31 US disclosed
WO-2002053158-A1 METHOD FOR TREATING GLAUCOMA IB ALTEON, INC. (US) 2002-07-11 WO disclosed
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC ALTEON, INC. 2002-06-06 US disclosed
WO-2002007725-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON, INC. (US) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE MMP1, COL1A1, COL2A1 SMN1; SMN2 605/4885LMNA 1024/4885ALDH1A1 175/4885
US-20020160993-A1 Method for treating glaucoma IC CHAT, MYOC, GAP43 SMN1; SMN2 3940/4885LMNA 2101/4885ALDH1A1 366/4885
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC MMP1, COL1A1, COL2A1 SMN1; SMN2 549/4885LMNA 1032/4885ALDH1A1 204/4885
US-20030176426-A1 Method for treating fibrotic diseases or other indications with imidazolium agents MMP1, COL1A1, COL2A1 SMN1; SMN2 204/4885LMNA 825/4885ALDH1A1 192/4885
US-20090124673-A1 Method for treating diabetic nephropathy REN, SLC5A2, SLC5A1 SMN1; SMN2 1693/4885LMNA 1911/4885ALDH1A1 402/4885
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID MMP1, COL1A1, COL2A1 SMN1; SMN2 295/4885LMNA 685/4885ALDH1A1 261/4885
US-20070043016-A1 Method of treating fibrotic diseases or other indications with imidazolium agents MMP1, COL1A1, EPX SMN1; SMN2 306/4885LMNA 473/4885ALDH1A1 431/4885
US-20090124674-A1 Method for treating congestive heart failure TNNI3, TNNT2, FABP3 SMN1; SMN2 2173/4885LMNA 1815/4885ALDH1A1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.